所有图片(1)
About This Item
经验公式（希尔记法）:
C18H38NO5P
CAS号:
分子量:
379.47
MDL编号:
UNSPSC代码:
12352211
PubChem化学物质编号:
NACRES:
NA.85
推荐产品
方案
≥98.0% (TLC)
表单
powder
组成
carbon content, 56.97%
hydrogen content, 10.09%
nitrogen content, 3.69%
脂质类型
sphingolipids
储存温度
−20°C
SMILES字符串
CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O
InChI
1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
InChI key
DUYSYHSSBDVJSM-KRWOKUGFSA-N
正在寻找类似产品? 访问 产品对比指南
应用
西尼莫德治疗骨质疏松症的再利用：一项研究重点介绍了西尼莫德（最初为多发性硬化症开发的S1P受体调节剂）通过影响鞘氨醇1-磷酸途径治疗骨质疏松症的潜力（Hu et al., 2024）。
鞘氨醇-1-磷酸在眼部健康中的作用：研究表明，鞘氨醇-1-磷酸受体1/5的选择性激动剂可以减轻眼部血管病变，表明其在眼病管理中具有治疗潜力，它还负责调节细胞存活、分化和增殖等多种细胞内过程（Nakamura et al., 2024）。
针对糖尿病肾病：研究探讨了车前子通过鞘氨醇激酶1/鞘氨醇-1-磷酸途径改善糖尿病肾病的机制，强调了该途径在代谢健康中的作用（Lan et al., 2024）。
神经退行性疾病治疗的进展：一篇综述聚焦于靶向鞘氨醇-1-磷酸受体的小分子调节剂的研究进展，为治疗神经退行性疾病指明了新方向（Sankar Kar et al., 2024）。
鞘氨醇-1-磷酸在眼部健康中的作用：研究表明，鞘氨醇-1-磷酸受体1/5的选择性激动剂可以减轻眼部血管病变，表明其在眼病管理中具有治疗潜力，它还负责调节细胞存活、分化和增殖等多种细胞内过程（Nakamura et al., 2024）。
针对糖尿病肾病：研究探讨了车前子通过鞘氨醇激酶1/鞘氨醇-1-磷酸途径改善糖尿病肾病的机制，强调了该途径在代谢健康中的作用（Lan et al., 2024）。
神经退行性疾病治疗的进展：一篇综述聚焦于靶向鞘氨醇-1-磷酸受体的小分子调节剂的研究进展，为治疗神经退行性疾病指明了新方向（Sankar Kar et al., 2024）。
生化/生理作用
可与S1P1 和S1P3 受体结合的脂质第二信使。调动细胞内Ca2+ 储备并降低细胞cAMP。激活磷脂酶D。S1P可刺激内皮细胞的迁移，但抑制其他细胞类型细胞的迁移。 诱导血管生成。
包装
无底玻璃瓶。内含物装在插入的融合锥内。
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Emmanuel E Egom et al.
Current opinion in lipidology, 24(4), 351-356 (2013-05-09)
The absolute level of HDL cholesterol (HDL-C) may not be the only criterion contributing to their antiatherothrombotic effects. This review focuses on evidence in support of the concept that HDL-bound sphingosine-1-phosphate (S1P) plays a role in different HDL atheroprotective properties
Alexander Koch et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 31(6), 745-760 (2013-06-06)
Because of its highly bioactive properties sphingosine 1-phosphate (S1P) is an attractive target for the treatment of several diseases. Since the expression of sphingosine kinases as well as S1P receptors was demonstrated in the kidney, questions about the physiological and
Roland Martin et al.
Current topics in microbiology and immunology, 378, 149-170 (2014-04-15)
The development of fingolimod, an unselective functional antagonist of the interactions between sphingosine 1 phosphate (S1P) and sphingosine 1 phosphate receptors (S1PRs), as the first oral therapy for multiple sclerosis (MS) has been a milestone. The parallel intensive research on
Tsuyoshi Nishi et al.
Biochimica et biophysica acta, 1841(5), 759-765 (2013-08-08)
Sphingosine 1-phosphate (S1P) is a lipid mediator that plays important roles in diverse cellular functions such as cell proliferation, differentiation and migration. S1P is synthesized inside the cells and subsequently released to the extracellular space, where it binds to specific
Gregory T Kunkel et al.
Nature reviews. Drug discovery, 12(9), 688-702 (2013-08-21)
The bioactive lipid sphingosine-1-phosphate (S1P) is involved in multiple cellular signalling systems and has a pivotal role in the control of immune cell trafficking. As such, S1P has been implicated in disorders such as cancer and inflammatory diseases. This Review
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门